Rae Myers

TL;DR: The safe starting dose of MV‐NIS for the clinical protocol was set at 1−2 × 104 TCID50/kg (106 TCID50 per patient), more so after pretreatment with cyclophosphamide.

TL;DR: E engineered MV‐Edm may be a potent and novel cancer gene therapy system for HCC and enable the spread of the virus to be monitored in a noninvasive manner.

TL;DR: It is concluded that the CPA regimen of four daily doses at 370 mg m–2 should be evaluated clinically with i.v. virotherapy to control the antiviral antibody response and facilitate effective repeat dosing.

TL;DR: The results support the safety of CNS administration of MV-CEA in glioma patients and show no clinical or biochemical evidence of toxicity, including lack of neurological symptoms, fever, or other systemic symptoms and lack of immunosuppression.

TL;DR: Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available, and commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents.